SubHero Banner

Tascenso ODT (fingolimod) – New formulation approval

On December 23, 2021, the FDA approved Handa Neuroscience’s Tascenso ODT (fingolimod) 0.25 mg orally disintegrating tablet, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg.

Download PDF